New hope for tough leukemia: trial tests powerful drug combo
NCT ID NCT06773936
Summary
This study is testing if adding a new drug, asciminib, to a standard treatment regimen works better for adults newly diagnosed with a specific, aggressive form of leukemia called Philadelphia chromosome-positive ALL. The goal is to see if this combination can drive the cancer into a deep, undetectable remission. About 55 participants will receive the drug combination in phases, with treatment lasting up to five years for those who respond well.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baptist Memorial Health Care
Memphis, Tennessee, 38120, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Northwell Health/Center for Advanced Medicine
Lake Success, New York, 11042, United States
-
UV Irvine Medical Center
Orange, California, 92868, United States
-
University of Cincinnati Cancer Ctr-UC Medical Ctr
Cincinnati, Ohio, 45267, United States
Conditions
Explore the condition pages connected to this study.